SIDE MEETINGS
Opt-in to attend additional learnings as part of your registration.
SAVAC 2.0 Forum
When: 3:00pm | Sunday 1 June
Where: Boulevard Rooms B1 & B2, BCEC
Join us for the SAVAC 2.0 Forum at the Lancefield Meeting to explore progress in Strep A surveillance, share experiences from our sentinel sites, and foster new collaborations.
This session is open to all Lancefield Meeting participants, including researchers, clinicians, and academic partners. Engage in discussions on diverse country experiences, surveillance strategies, and the future of Strep A vaccine development.
The Lancefield Society AGM
When: 12:45pm | Tuesday 3 June
Where: Boulevard Auditorium, BCEC
Access: The Lancefield Society Members
Join the Lancefield Committee, and their members, at their Annual General Meeting onsite at the LISSSD 2025 Scientific Meeting.
Hear about the past performance, contribute to the future of the society and vote on the new committee members.
ARF Treatment Trials Update
When: 2:00pm | Tuesday 3 June
Where: Level Twelve North, Rydges South Bank
Registration: Email ecorrigan@adhb.govt.nz
All conference attendees interested in contributing to ARF treatment trials, are warmly invited to attend. This session will include an update about TREAT-SC, the Australia-New Zealand Sydenham’s Chorea Trial. We will also discuss plans for an adaptive platform trial for immunomodulatory treatments for carditis in ARF. Jointly organised by Aotearoa New Zealand (the Starship Children’s Hospital Research Hub and Rapua Te Mea Ngaro Ka Tau) and the Menzies School of Health Research.
Pfizer Breakfast Symposium
The human challenge model in vaccine development and implementation.
When: 7:45am | Wednesday 4 June
Where: Boulevard Rooms B1 & B2, BCEC
Speakers: Paul Licciardi, Joshua Osowicki, Sharon Lewin, Annaliesa Anderson (Chair)
Catering: Breakfast will be provided
In this workshop, we will delve into various aspects of human challenge models (HCMs) and discuss the potential and challenges associated with them in the advancement of vaccine development and implementation. We will address their application in accelerating insights into vaccine efficacy, the ethical considerations surrounding their use, and the regulatory pathways for incorporating HCM data into vaccine approval and/or recommendation processes. Experts in the field will discuss how HCMs can bridge the gap between early-stage vaccine development and clinical implementation, ultimately enhancing the speed and efficiency of bringing new vaccines to market.
This workshop will bring together attendees across academia and industry to foster collaborative discussions on the future of vaccine development, leveraging the potential of human challenge models to address global health challenges.
